- Home
- FT vs TLSI Comparison
FT vs TLSI Comparison
Compare FT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- TLSI
- Stock Information
- Founded
- FT 1988
- TLSI 2010
- Country
- FT United States
- TLSI United States
- Employees
- FT N/A
- TLSI N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- TLSI Medical Specialities
- Sector
- FT Finance
- TLSI Health Care
- Exchange
- FT Nasdaq
- TLSI Nasdaq
- Market Cap
- FT 171.4M
- TLSI 166.8M
- IPO Year
- FT N/A
- TLSI N/A
- Fundamental
- Price
- FT $7.44
- TLSI $4.67
- Analyst Decision
- FT
- TLSI Strong Buy
- Analyst Count
- FT 0
- TLSI 3
- Target Price
- FT N/A
- TLSI $12.67
- AVG Volume (30 Days)
- FT 63.0K
- TLSI 77.7K
- Earning Date
- FT 01-01-0001
- TLSI 11-12-2024
- Dividend Yield
- FT 7.85%
- TLSI N/A
- EPS Growth
- FT N/A
- TLSI N/A
- EPS
- FT N/A
- TLSI N/A
- Revenue
- FT N/A
- TLSI $24,736,000.00
- Revenue This Year
- FT N/A
- TLSI $61.24
- Revenue Next Year
- FT N/A
- TLSI $47.32
- P/E Ratio
- FT N/A
- TLSI N/A
- Revenue Growth
- FT N/A
- TLSI 67.75
- 52 Week Low
- FT $5.97
- TLSI $3.32
- 52 Week High
- FT $7.23
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- FT 74.94
- TLSI 36.08
- Support Level
- FT $7.31
- TLSI $4.43
- Resistance Level
- FT $7.33
- TLSI $5.32
- Average True Range (ATR)
- FT 0.06
- TLSI 0.36
- MACD
- FT 0.01
- TLSI -0.04
- Stochastic Oscillator
- FT 84.38
- TLSI 18.49
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.